- Home
- GORV vs STTK Comparison
GORV vs STTK Comparison
Compare GORV & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORV
- STTK
- Stock Information
- Founded
- GORV 1976
- STTK 2016
- Country
- GORV United States
- STTK United States
- Employees
- GORV N/A
- STTK N/A
- Industry
- GORV Retail-Auto Dealers and Gas Stations
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- GORV Consumer Discretionary
- STTK Health Care
- Exchange
- GORV Nasdaq
- STTK Nasdaq
- Market Cap
- GORV 31.8M
- STTK 37.6M
- IPO Year
- GORV 2015
- STTK 2020
- Fundamental
- Price
- GORV $0.26
- STTK $1.13
- Analyst Decision
- GORV Hold
- STTK Hold
- Analyst Count
- GORV 2
- STTK 4
- Target Price
- GORV $2.00
- STTK $3.00
- AVG Volume (30 Days)
- GORV 24.1M
- STTK 98.3K
- Earning Date
- GORV 05-15-2025
- STTK 05-01-2025
- Dividend Yield
- GORV N/A
- STTK N/A
- EPS Growth
- GORV N/A
- STTK N/A
- EPS
- GORV N/A
- STTK N/A
- Revenue
- GORV $767,257,000.00
- STTK $4,606,000.00
- Revenue This Year
- GORV $15.65
- STTK N/A
- Revenue Next Year
- GORV $20.54
- STTK N/A
- P/E Ratio
- GORV N/A
- STTK N/A
- Revenue Growth
- GORV N/A
- STTK 69.65
- 52 Week Low
- GORV $0.13
- STTK $0.69
- 52 Week High
- GORV $3.75
- STTK $7.49
- Technical
- Relative Strength Index (RSI)
- GORV 51.90
- STTK 53.12
- Support Level
- GORV $0.25
- STTK $0.98
- Resistance Level
- GORV $0.29
- STTK $1.13
- Average True Range (ATR)
- GORV 0.06
- STTK 0.10
- MACD
- GORV 0.01
- STTK 0.00
- Stochastic Oscillator
- GORV 34.45
- STTK 54.55
About GORV Lazydays Holdings Inc.
Lazydays Holdings Inc operates recreational vehicle dealerships. It provides products and services for RV owners and outdoor enthusiasts. The company generates revenue by providing a full spectrum of RV products: New and pre-owned RV sales, RV parts and services, financing and insurance products, third-party protection plans, after-market parts and accessories, and RV camping facilities.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.